

Pagibaximab

| | |
|-----------|---|
| Cat. No.: | HY-P99309 |
| CAS No.: | 595566-61-3 |
| Target: | Bacterial |
| Pathway: | Anti-infection |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | |
|---------------------------|---|
| Description | Pagibaximab is a chimeric IgG1 antibody recognizing the surface component lipoteichoic acid of <i>S. aureus</i> and <i>S. epidermidis</i> . Pagibaximab can be used to prevent staphylococcal sepsis ^[1] . |
| IC ₅₀ & Target | <i>S. epidermidis</i> lipoteichoic acid ^[1] |

REFERENCES

[1]. Weisman LE, et, al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. *Pediatrics*. 2011 Aug;128(2):271-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA